Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 19/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | PRKACG | P22612 | 1/20 | 0.43 |
| ▸ | PRKACB | P22694 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 16/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830960 | 0.97 | FGFR4 (0.46) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL5830612 | 0.91 | FGFR4 (0.53) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL5773167 | 0.87 | FGFR4 (0.33) | FGFR4EGFRPDGFRBFGFR1FGFR2 | |
| SCHEMBL5773162 | 0.87 | FGFR4 (0.33) | FGFR4EGFRPDGFRBFGFR1FGFR2 | |
| SCHEMBL5831565 | 0.86 | FGFR4 (0.54) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL5831572 | 0.86 | FGFR4 (0.54) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL5769897 | 0.84 | EGFR (0.51) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL5769890 | 0.84 | EGFR (0.51) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL5831097 | 0.83 | FGFR4 (0.54) | FGFR4EGFRPDGFRBFGFR1PDGFRA | |
| SCHEMBL5831099 | 0.83 | FGFR4 (0.54) | FGFR4EGFRPDGFRBFGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | FGFR4 3/4885EGFR 41/4885PDGFRB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.